BPS3082 Chap.8 Delayed Effects and PBPK
Delayed Effects and PBPK
A delayed effect requires a model that explains what physically or biologically takes time. In an effect-compartment model, drug equilibrates from plasma to a hypothetical biophase and the response is driven by effect-site rather than immediate plasma concentration. In an indirect-response model, drug inhibits or stimulates production or loss of an endogenous quantity; the measured response then changes through turnover.
Both structures can create a lag, but they encode different mechanisms and make different predictions under changed regimens. The direction of an indirect response helps define the candidate structure. Inhibiting input or stimulating loss tends to lower the response, while stimulating input or inhibiting loss tends to raise it.
The answer must name both the drug action and the affected process because 'inhibition model' alone is ambiguous. Effect-compartment reasoning instead focuses on distribution to the action site, equilibration rate and the time relation between plasma, biophase and response.
Biology, signature profiles, dose-dependent delay, parameter credibility and diagnostics are combined rather than allowing one curve shape to dictate the model. Physiologically based pharmacokinetic modelling serves a separate role. PBPK represents organs, blood flows and compound-specific processes to describe disposition and support translation across species, populations or conditions.
Its predicted concentrations may feed a PD model, but PBPK is not another indirect-response category. Greater mechanistic detail also creates a larger input and sensitivity burden. This chapter therefore asks students to state the mechanism, verify the timing with adequate sampling, compare plausible candidates and identify an observation that could refute the preferred choice.
Sparse response measurements around the peak can manufacture an apparent lag, so observation windows are part of the evidence.
What this chapter covers
- 01
Effect-compartment delay
- 02
Biophase concentration
- 03
Indirect-response turnover
- 04
Input and loss pathways
- 05
Signature profiles
- 06
PBPK development role
- 07
Biophase distribution versus biomarker turnover
- 08
Input and loss perturbation directions
- 09
Sampling around concentration and effect peaks
- 10
Mechanistic inputs and sensitivity burden
Worked example · free
Choose a turnover model
- +2Identify that drug changes production of an endogenous biomarker rather than only distribution to a site.
- +2Choose an indirect-response model with inhibition of input.
- +2Explain that existing biomarker continues to be lost, so turnover creates the delayed minimum.
Key terms
- Effect Compartment
- A hypothetical biophase representing delayed equilibration between plasma and the action site.
- Indirect Response
- A model where drug changes production or loss of an endogenous response.
- Turnover
- The continuing input and loss processes that maintain or restore a biomarker.
- Signature Profile
- A characteristic effect-time shape used with biology to distinguish model mechanisms.
- PBPK
- Mechanistic pharmacokinetic modelling based on physiological compartments and compound properties.
Delayed Effects and PBPK FAQ
What causes delay in an effect-compartment model?
The delay represents time needed for drug to equilibrate from plasma to the action site. The response model is driven by effect-site concentration rather than immediate plasma concentration. Check peak timing, hysteresis and whether the equilibration parameter is supported by sufficiently dense concentration and response sampling.
What causes delay in an indirect-response model?
Drug alters input or loss of an endogenous substance, and the measured response changes through biological turnover. The delay reflects accumulation, depletion or recovery of that response. Specify whether drug inhibits or stimulates input or loss, because those four structures predict different directions and recovery profiles.
Is PBPK another indirect-response model?
No. PBPK mechanistically represents drug disposition through physiological tissues, flows and compound properties. Its predicted concentrations can feed a PD model, but it answers a different structural question from biomarker turnover. Its greater detail also requires more inputs, sensitivity analysis and explicit treatment of uncertain assumptions.
Assessment move
For each delayed profile, write the proposed physical cause of delay before choosing a model. Draw the concentration-time and effect-time curves together, mark both peaks, and ask whether the lag is compatible with biophase distribution, endogenous turnover or sparse sampling.
Practise the four indirect-response directions—inhibit input, inhibit loss, stimulate input and stimulate loss—and link each to whether the response rises or falls from baseline. For effect-compartment cases, explain what the equilibration parameter represents and which timing observations identify it.
Compare dose-dependent delay, hysteresis direction, biological pathway and residual patterns as supporting evidence, then name an observation that could refute the choice. Keep PBPK separate as a mechanistic disposition framework: list the physiological and compound inputs it requires, the translation question it serves and the uncertainty burden it introduces.
Finish short answers with mechanism, profile signature, diagnostic and limitation rather than using a model name alone. Construct a two-column mechanism test in which the same delayed observation is explained once by biophase distribution and once by biomarker turnover. Under each explanation, list the next sampling time, biological measurement and regimen change that would be most discriminating.
For indirect response, rehearse return-to-baseline reasoning as well as the initial direction. For PBPK, draw a boundary around disposition inputs and show where a separate effect model begins. This prevents mechanistic detail from obscuring the actual question and makes model falsification part of every answer.
